ANI Pharmaceuticals, Inc. (ANIP)
After hours:
Chart Events
Performance Outlook
| Previous Close | 27.22 |
| Open | 27.44 |
| Bid | 20.00 x 800 |
| Ask | 46.84 x 1000 |
| Day's Range | 26.99 - 29.81 |
| 52 Week Range | 22.31 - 60.23 |
| Volume | |
| Avg. Volume | 116,393 |
| Market Cap | 481.924M |
| Beta (5Y Monthly) | 1.19 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.83 |
| Earnings Date | Mar 07, 2022 - Mar 11, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 40.67 |
- Zacks
Veeva Systems (VEEV) Inks Deal to Serve Rare Disease Patients
Adoption of Veeva Systems' (VEEV) cloud applications is likely to significantly boost its Veeva Development Cloud business.
- Business Wire
ANI Pharmaceuticals Announces FDA Approval and Imminent Launch of Clorazepate Dipotassium Tablets USP
BAUDETTE, Minn., June 22, 2022--ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that the Company received U.S. Food and Drug Administration (FDA) approval for the Abbreviated New Drug Application (ANDA) for Clorazepate Dipotassium Tablets.
- PR Newswire
ANI Pharmaceuticals Adopts Veeva Commercial Cloud to Better Support Rare Disease Patients
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) and Veeva Systems (NYSE: VEEV) today announced a collaboration to define and operationalize data-driven commercial strategies for ANI's new Rare Disease Business Unit. ANI is using software, data, and services from Veeva to establish the digital foundation for the launch of the business unit's first commercially available product in the U.S.
